HomeCompareITCI vs MO

ITCI vs MO: Dividend Comparison 2026

ITCI yields 1.52% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $55.8K in total portfolio value· pulled ahead in Year 4
10 years
ITCI
ITCI
● Live price
1.52%
Share price
$131.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$167.32
Full ITCI calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — ITCI vs MO

📍 MO pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITCIMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITCI + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITCI pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITCI
Annual income on $10K today (after 15% tax)
$128.91/yr
After 10yr DRIP, annual income (after tax)
$142.22/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $24,481.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITCI + MO for your $10,000?

ITCI: 50%MO: 50%
100% MO50/50100% ITCI
Portfolio after 10yr
$49.8K
Annual income
$14,567.93/yr
Blended yield
29.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ITCI
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$98.50
-25.3% upside vs current
Range: $70.00 — $132.00
Altman Z
38.0
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITCI buys
0
MO buys
0
No recent congressional trades found for ITCI or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITCIMO
Forward yield1.52%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$21.9K$77.7K
Annual income after 10y$167.32$28,968.54
Total dividends collected$1.6K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$98.50$61.25

Year-by-year: ITCI vs MO ($10,000, DRIP)

YearITCI PortfolioITCI Income/yrMO PortfolioMO Income/yrGap
1$10,852$151.66$10,558$768.31+$294.00ITCI
2$11,765$153.81$11,352$1,015.87+$413.00ITCI
3$12,745$155.85$12,482$1,367.86+$263.00ITCI
4← crossover$13,794$157.78$14,103$1,883.39$309.00MO
5$14,920$159.61$16,472$2,664.91$1.6KMO
6$16,125$161.33$20,024$3,897.79$3.9KMO
7$17,417$162.96$25,537$5,933.74$8.1KMO
8$18,801$164.50$34,478$9,476.77$15.7KMO
9$20,283$165.95$49,776$16,022.63$29.5KMO
10$21,870$167.32$77,699$28,968.54$55.8KMO

ITCI vs MO: Complete Analysis 2026

ITCIStock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Full ITCI Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ITCI vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITCI vs SCHDITCI vs JEPIITCI vs OITCI vs KOITCI vs MAINITCI vs PMITCI vs BTIITCI vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.